Europe
The National Institutes of Health is raising concern about the safety of AstraZeneca’s coronavirus vaccine, even as the U.S. FDA is weighing whether or not to resume testing in the United States following a global pause in the trial for safety reasons.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
Only days after saying it expects to have key data from its Phase III clinical trial of its COVID-19 vaccine in October, Germany’s BioNTech received a grant of up to €375 million from the German Federal Ministry of Education and Research.
In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.
AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
It was a busy week for clinical trial updates. Here’s a look.
The financing will be used by MiNA to advance the company’s pipeline of proprietary, first-in-class, small activating RNA therapeutics.
Despite a temporary pause on its COVID-19 vaccine trial, AstraZeneca Chief Executive Officer Pascal Soriot said the preventative drug could still be available for commercial use by the end of the year, or in early 2021 barring any other setback.
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES